1. Home
  2. BEAT vs TVGN Comparison

BEAT vs TVGN Comparison

Compare BEAT & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Heartbeam Inc.

BEAT

Heartbeam Inc.

HOLD

Current Price

$0.28

Market Cap

22.7M

Sector

Technology

ML Signal

HOLD

Logo Tevogen Bio Holdings Inc.

TVGN

Tevogen Bio Holdings Inc.

SELL

Current Price

$6.10

Market Cap

21.3M

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
BEAT
TVGN
Founded
2015
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Blank Checks
Sector
Technology
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
22.7M
21.3M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
BEAT
TVGN
Price
$0.28
$6.10
Analyst Decision
Buy
Analyst Count
3
0
Target Price
★ $2.13
N/A
AVG Volume (30 Days)
★ 1.1M
7.8K
Earning Date
11-12-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 15.07
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.30
$0.14
52 Week High
$4.00
$24.91

Technical Indicators

Market Signals
Indicator
BEAT
TVGN
Relative Strength Index (RSI) 30.83 48.25
Support Level N/A $5.01
Resistance Level $0.52 $7.22
Average True Range (ATR) 0.03 0.42
MACD -0.01 0.08
Stochastic Oscillator 3.35 53.23

Price Performance

Historical Comparison
BEAT
TVGN

About BEAT Heartbeam Inc.

HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.

About TVGN Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.

Share on Social Networks: